source
- Novo Nordisk's anti-inflammatory drug ziltivekimab fails to cut major heart events in Phase 3 trialNovo Nordisk reported that its investigational anti‑inflammatory antibody, ziltivekimab, did not reduce the incidence of major cardiovascular events in a pivotal Phase 3 study. The trial enrolled…
- AbbVie shares slip 4% as Q2 immunology earnings beat falls short of lofty expectationsAbbVie’s stock fell about 4% on Friday after the company reported second‑quarter results that modestly exceeded analyst forecasts, disappointing investors who had set very high expectations. The f…